Travere Therapeutics
TVTX
124 hedge funds and large institutions have $643M invested in Travere Therapeutics in 2020 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 49 reducing their positions, and 26 closing their positions.
5% more capital invested
Capital invested by funds: $611M → $643M (+$31.6M)
1.98% more ownership
Funds ownership: 100.14% → 102.12% (+2%)
5% less funds holding
Funds holding: 131 → 124 (-7)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
35% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 49
63% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $4.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.5M |
| 2 |
Goldman Sachs
New York
|
+$8.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.51M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$6.48M |
| 5 |
Renaissance Technologies
New York
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.97M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$4.75M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.51M |
| 4 |
Two Sigma Investments
New York
|
-$4.28M |
| 5 |
SCM
Scopia Capital Management
New York
|
-$4.13M |
TVTX Hedge Fund Activity: Q1 2020 in Review
124 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2020, worth a combined $643M — up 5.2% from $611M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TVTX and 20 opened new positions — a net loss of 6 holders — while 49 trimmed existing stakes and 32 added.
The largest buyer was Adage Capital Partners, adding an estimated $14.5M. The largest seller was Millennium Management, cutting an estimated $8.97M.
- 124 institutional investors held Travere Therapeutics (TVTX) as of Q1 2020, down from 131 in Q4 2019.
- Funds reported $643M of Travere Therapeutics stock for Q1 2020, up 5.2% quarter-over-quarter.
- 20 funds opened new Travere Therapeutics positions in Q1 2020 and 26 closed out, a net change of -6 holders.
- The largest Travere Therapeutics buyer in Q1 2020 was Adage Capital Partners, an estimated $14.5M added.
- The largest Travere Therapeutics seller in Q1 2020 was Millennium Management, an estimated $8.97M sold.
Based on aggregated 13F filings for Q1 2020.